Literature DB >> 31905021

Mechanisms underlying reduced weight gain in intestinal fatty acid-binding protein (IFABP) null mice.

Atreju I Lackey1,2, Tina Chen1, Yin X Zhou1, Natalia M Bottasso Arias3, Justine M Doran1, Sophia M Zacharisen1, Angela M Gajda1,2, William O Jonsson1,2, Betina Córsico3, Tracy G Anthony1,2, Laurie B Joseph2,4, Judith Storch1,2.   

Abstract

Intestinal-fatty acid binding protein (IFABP; FABP2) is a 15-kDa intracellular protein abundantly present in the cytosol of the small intestinal (SI) enterocyte. High-fat (HF) feeding of IFABP-/- mice resulted in reduced weight gain and fat mass relative to wild-type (WT) mice. Here, we examined intestinal properties that may underlie the observed lean phenotype of high fat-fed IFABP-/- mice. No alterations in fecal lipid content were found, suggesting that the IFABP-/- mice are not malabsorbing dietary fat. However, the total excreted fecal mass, normalized to food intake, was increased for the IFABP-/- mice relative to WT mice. Moreover, intestinal transit time was more rapid in the IFABP-/- mice. IFABP-/- mice displayed a shortened average villus length, a thinner muscularis layer, reduced goblet cell density, and reduced Paneth cell abundance. The number of proliferating cells in the crypts of IFABP-/- mice did not differ from that of WT mice, suggesting that the blunt villi phenotype is not due to alterations in proliferation. IFABP-/- mice were observed to have altered expression of genes and proteins related to intestinal structure, while immunohistochemical analyses revealed increased staining for markers of inflammation. Taken together, these studies indicate that the ablation of IFABP, coupled with high-fat feeding, leads to changes in gut motility and morphology, which likely contribute to the relatively leaner phenotype occurring at the whole-body level. Thus, IFABP is likely involved in dietary lipid sensing and signaling, influencing intestinal motility, intestinal structure, and nutrient absorption, thereby impacting systemic energy metabolism.NEW & NOTEWORTHY Intestinal fatty acid binding protein (IFABP) is thought to be essential for the efficient uptake and trafficking of dietary fatty acids. In this study, we demonstrate that high-fat-fed IFABP-/- mice have an increased fecal output and are likely malabsorbing other nutrients in addition to lipid. Furthermore, we observe that the ablation of IFABP leads to marked alterations in intestinal morphology and secretory cell abundance.

Entities:  

Keywords:  IFABP; intestine; lipid; morphology; nutrition

Mesh:

Substances:

Year:  2020        PMID: 31905021      PMCID: PMC7099495          DOI: 10.1152/ajpgi.00120.2019

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  79 in total

1.  Direct comparison of mice null for liver or intestinal fatty acid-binding proteins reveals highly divergent phenotypic responses to high fat feeding.

Authors:  Angela M Gajda; Yin Xiu Zhou; Luis B Agellon; Susan K Fried; Sarala Kodukula; Walter Fortson; Khamoshi Patel; Judith Storch
Journal:  J Biol Chem       Date:  2013-08-29       Impact factor: 5.157

2.  c-Jun N-terminal kinase 2 promotes enterocyte survival and goblet cell differentiation in the inflamed intestine.

Authors:  A D Mandić; E Bennek; J Verdier; K Zhang; S Roubrocks; R J Davis; B Denecke; N Gassler; K Streetz; A Kel; M Hornef; F J Cubero; C Trautwein; G Sellge
Journal:  Mucosal Immunol       Date:  2017-01-18       Impact factor: 7.313

3.  Impact of L-FABP and glucose on polyunsaturated fatty acid induction of PPARα-regulated β-oxidative enzymes.

Authors:  Anca D Petrescu; Huan Huang; Gregory G Martin; Avery L McIntosh; Stephen M Storey; Danilo Landrock; Ann B Kier; Friedhelm Schroeder
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-12-13       Impact factor: 4.052

4.  Decreased body weight and hepatic steatosis with altered fatty acid ethanolamide metabolism in aged L-Fabp -/- mice.

Authors:  Elizabeth P Newberry; Susan M Kennedy; Yan Xie; Jianyang Luo; Rosanne M Crooke; Mark J Graham; Jin Fu; Daniele Piomelli; Nicholas O Davidson
Journal:  J Lipid Res       Date:  2012-02-10       Impact factor: 5.922

5.  XBP1U inhibits the XBP1S-mediated upregulation of the iNOS gene expression in mammalian ER stress response.

Authors:  Fengjin Guo; Edward A Lin; Ping Liu; Jianwei Lin; Chuanju Liu
Journal:  Cell Signal       Date:  2010-07-15       Impact factor: 4.315

6.  Localization, function and regulation of the two intestinal fatty acid-binding protein types.

Authors:  Emile Levy; Daniel Ménard; Edgard Delvin; Alain Montoudis; Jean-François Beaulieu; Geneviève Mailhot; Nadia Dubé; Daniel Sinnett; Ernest Seidman; Moise Bendayan
Journal:  Histochem Cell Biol       Date:  2009-06-05       Impact factor: 4.304

7.  Differential endoplasmic reticulum stress signaling pathways mediated by iNOS.

Authors:  Yi-Hsuan Hsieh; Ih-Jen Su; Huan-Yao Lei; Ming-Derg Lai; Wen-Wei Chang; Wenya Huang
Journal:  Biochem Biophys Res Commun       Date:  2007-05-30       Impact factor: 3.575

8.  XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease.

Authors:  Arthur Kaser; Ann-Hwee Lee; Andre Franke; Jonathan N Glickman; Sebastian Zeissig; Herbert Tilg; Edward E S Nieuwenhuis; Darren E Higgins; Stefan Schreiber; Laurie H Glimcher; Richard S Blumberg
Journal:  Cell       Date:  2008-09-05       Impact factor: 41.582

Review 9.  Celiac Disease: A Review of Current Concepts in Pathogenesis, Prevention, and Novel Therapies.

Authors:  Jason A Tye-Din; Heather J Galipeau; Daniel Agardh
Journal:  Front Pediatr       Date:  2018-11-21       Impact factor: 3.418

10.  High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway.

Authors:  Kyung-Ah Kim; Wan Gu; In-Ah Lee; Eun-Ha Joh; Dong-Hyun Kim
Journal:  PLoS One       Date:  2012-10-16       Impact factor: 3.240

View more
  7 in total

1.  Intestinal Enteroendocrine Cell Signaling: Retinol-binding Protein 2 and Retinoid Actions.

Authors:  Rossana M Calderon; Christopher A Smith; Emily L Miedzybrodzka; Josie A Silvaroli; Marcin Golczak; Fiona M Gribble; Frank Reimann; William S Blaner
Journal:  Endocrinology       Date:  2022-07-01       Impact factor: 5.051

2.  Gut Microbiota and Phenotypic Changes Induced by Ablation of Liver- and Intestinal-Type Fatty Acid-Binding Proteins.

Authors:  Guojun Wu; Hiba R Tawfeeq; Atreju I Lackey; Yinxiu Zhou; Zoe Sifnakis; Sophia M Zacharisen; Heli Xu; Justine M Doran; Harini Sampath; Liping Zhao; Yan Y Lam; Judith Storch
Journal:  Nutrients       Date:  2022-04-22       Impact factor: 6.706

3.  Two fatty acid-binding proteins expressed in the intestine interact differently with endocannabinoids.

Authors:  May Poh Lai; Francine S Katz; Cédric Bernard; Judith Storch; Ruth E Stark
Journal:  Protein Sci       Date:  2020-04-28       Impact factor: 6.725

Review 4.  From Congenital Disorders of Fat Malabsorption to Understanding Intra-Enterocyte Mechanisms Behind Chylomicron Assembly and Secretion.

Authors:  Emile Levy; Jean François Beaulieu; Schohraya Spahis
Journal:  Front Physiol       Date:  2021-01-27       Impact factor: 4.566

Review 5.  Lipidome is lipids regulator in gastrointestinal tract and it is a life collar in COVID-19: A review.

Authors:  Khaled Mohamed Mohamed Koriem
Journal:  World J Gastroenterol       Date:  2021-01-07       Impact factor: 5.742

6.  I-FABP is decreased in COVID-19 patients, independently of the prognosis.

Authors:  Kevin Guedj; Mathieu Uzzan; Damien Soudan; Catherine Trichet; Antonino Nicoletti; Emmanuel Weiss; Hana Manceau; Alexandre Nuzzo; Olivier Corcos; Xavier Treton; Katell Peoc'h
Journal:  PLoS One       Date:  2021-04-15       Impact factor: 3.240

7.  Alterations of mucosa-attached microbiome and epithelial cell numbers in the cystic fibrosis small intestine with implications for intestinal disease.

Authors:  Jennifer Kelly; Miran Al-Rammahi; Kristian Daly; Paul K Flanagan; Arun Urs; Marta C Cohen; Gabriella di Stefano; Marcel J C Bijvelds; David N Sheppard; Hugo R de Jonge; Ursula E Seidler; Soraya P Shirazi-Beechey
Journal:  Sci Rep       Date:  2022-04-21       Impact factor: 4.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.